Medication Treatments

HHS Eliminates X-Waiver Requirement for DEA-Licensed Physicians
HHS is publishing new guidelines that will expand access to medication-assisted treatment for opioid use disorder by exempting physicians from certain certification requirements necessary for prescribing buprenorphine.
Medication-Assisted Treatment for Methamphetamine Use Disorder? NIH Study Shows Potential
Results of a clinical trial published by NIH on Wednesday showed that a combination of two medications—injectable naltrexone and oral bupropion—were safe and effective in the treatment of adults with moderate or severe methamphetamine use disorder.
Physician-Pharmacist Buprenorphine Treatment Collaboration Shows Strong Returns
Results of a NIDA-supported pilot study released on Monday showed that collaboration between physicians and pharmacists could lead to improved medication adherence among patients being treated for opioid use disorder.
Stimulant Summit: Providers Must Weather Storm as COVID Complicates Stimulant Surge
With the lethality, availability and use of stimulants all greatly increasing in the U.S. in recent years and the COVID-19 pandemic complicating the treatment landscape for patients and practitioners alike, it’s critical for providers to weather the storm, Deni Carise, PhD, chief science officer for Recovery Centers of America, told Cocaine, Meth & Stimulant Summit attendees in a Saturday session.
Indiana University Researchers to Study Use of Tezampanel for Opioid Withdrawal
The Indiana University School of Medicine has received a $12.3 million grant from the National Institute on Drug Abuse for a two-stage research project to study the use of tezampanel to treat opioid withdrawal syndrome, as well as other addictions and mental illnesses.
Spectrum to Provide MAT Services for Incarcerated Individuals in Massachusetts
Spectrum Health Systems announced that it has been awarded a four-year, $43.5 million contract by the Massachusetts Department of Correction to provide medication-assisted treatment to incarcerated offenders.
FDA Seeks Public Input on Patient-Focused Drug Development for Stimulant Use Disorder
The FDA will conduct a virtual public meeting on patient-focused drug development for stimulant use disorder on Oct. 6, and is seeking input from individuals and families impacted by stimulant use.
Temple Researchers Receive NIDA Grant to Study Cocaine Addiction Treatment
Researchers at Temple University have received a $1.77 million grant from the National Institute on Drug Abuse to study the effects of a therapy for the treatment of cocaine use disorder, according to a media report.
1 in 5 Emergency Dept. Physicians Ready to Offer Buprenorphine
A Yale study of 400 clinicians found that just 21% of emergency department clinicians say they are prepared to prescribe buprenorphine for the treatment of opioid use disorder.
Elevate Spotlight: Best Practices in Opioid Addiction Treatment
With the far reach of the opioid epidemic and the high comorbidity of opioid addiction with other psychiatric disorders, the session will be relevant to all attendees, not just those in addiction medicine.
NCAD West: Prescription Opioid Misuse Drops, but Providers Need to Stay Vocal
During the opening plenary of NCAD West on Thursday, Colorado Consortium for Prescription Drug Abuse director Rober Valuck, PhD, RPh, FNAP, implored attendees to aggressively fight barriers to treatment, scrutinize their own work, and learn from their peers.
Back to Top